Research Topics
Species | Frits van RheeSummaryAffiliation: University of Arkansas for Medical Sciences Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Highly activated and expanded natural killer cells for multiple myeloma immunotherapyTarun K Garg
Myeloma Institute for Research and Therapy University of Arkansas for Medical Sciences 4301 West Markham, Little Rock, AR 72205 USA
Haematologica 97:1348-56. 2012....- NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responsesFrits van Rhee
University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, 4301 West Markham, no 776, Little Rock, AR 72205, USA
Blood 105:3939-44. 2005..The pool of NY-ESO-1-specific cytotoxic T cells expands easily on NY-ESO-1 peptide stimulation and is functionally active. NY-ESO-1 should therefore be an ideal tumor target antigen for immunotherapy of patients with poor-prognosis MM... 
Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients?Frits van Rhee
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AR 72205, USA
Nat Clin Pract Oncol 5:70-1. 2008- Castleman disease in the 21st century: an update on diagnosis, assessment, and therapyFrits van Rhee
University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock, AR 72205, USA
Clin Adv Hematol Oncol 8:486-98. 2010..Important strides forward have also been made in the management of HIV-positive CD... - Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myelomaFrits van Rhee
University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock AR 72205, USA
Mol Cancer Ther 8:2616-24. 2009.... 
Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's diseaseFrits van Rhee
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AR 72205, USA
J Clin Oncol 28:3701-8. 2010..Siltuximab is a new anti-IL-6, chimeric monoclonal antibody with potential therapeutic benefit in patients with CD...- Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3Bart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 138:176-85. 2007..Results of this phase-2 study demonstrated that bortezomib could be safely combined with multi-agent chemotherapy, effecting near-complete remission status and 2-year survival rates in more than 80% of patients... - High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patientsMauricio Pineda-Roman
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
Cancer 112:1754-64. 2008..In this report, the authors describe their collective experience with melphalan-based autotransplants since the inception of their program at the University of Arkansas for Medical Sciences in 1989... - Thalidomide and hematopoietic-cell transplantation for multiple myelomaBart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
N Engl J Med 354:1021-30. 2006..High-dose therapy with melphalan can prolong survival among patients with multiple myeloma. We assessed whether the addition of thalidomide, which has activity against advanced and refractory myeloma, would further improve survival... - Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenanceBijay Nair
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 115:4168-73. 2010..The robustness of the GEP risk model should be exploited in clinical trials aimed at improving the notoriously poor outcome in high-risk disease... - Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survivalBijay Nair
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72205, USA
Blood 113:6572-5. 2009..001). Based on its PRS predictive power, GEP analysis should be an integral part of new agent trials in search of better therapy for high-risk myeloma... - International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocolsSarah Waheed
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
Cancer 117:1001-9. 2011.... - Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering diseaseMauricio Pineda Roman
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 136:393-9. 2007..In comparison with U-MM, E-MM evolved from MGUS/SMM was associated with lower CR rate without adversely affecting survival. In contrast, CR was an independent favourable feature for survival in U-MM... - Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2Mauricio Pineda-Roman
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 140:625-34. 2008..Our data strongly suggest that the addition of bortezomib in TT3 was accountable for its superior performance rather than greater compliance with protocol completion as a result of greater dose-density in TT3 vs. TT2... - Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioningChoon Kee Lee
The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR, USA
Exp Hematol 31:73-80. 2003..The aim of this study was to identify prognostic factors for outcome of high-risk patients with multiple myeloma after allogeneic transplantation prepared by reduced intensity conditioning (RIC)... - DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myelomaChoon Kee Lee
The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Slot 776, 4301 West Markham, Little Rock, AR 72205, USA
J Clin Oncol 21:2732-9. 2003..To improve outcome in previously treated patients (at least two cycles of standard therapy) with multiple myeloma, thalidomide was combined with cytotoxic chemotherapy as induction therapy... - Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic diseaseBart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
Blood 112:3122-5. 2008..Trial registered at http://www.clinicaltrials.gov under identifier NCT00083382... - Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapyFrits van Rhee
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 116:1220-7. 2010.... - Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profileYiming Zhou
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham 816, Little Rock, AR 72205, USA
Br J Haematol 145:637-41. 2009..42, P = 0.004). The prevalence of high-risk myeloma in the RS+/FL+ group may reflect a dissemination-prone condition not shared by the other three groups... - Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalitiesBart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
Blood 112:3115-21. 2008..008). Because two thirds of patients without CAs have remained alive at 7 years, the presently emerging separation in favor of thalidomide may eventually reach statistical significance as well... - Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapiesBart Barlogie
Medicine and Pathology, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 107:2633-8. 2006..The favorable effects of CR and rapidly sequenced second transplantation attest to the validity of a melphalan dose-response effect in myeloma... - Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosisFenghuang Zhan
Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock 72205, USA
Blood 109:1692-700. 2007..01). The MGUS-L signature was also seen in plasma cells from 15 of 20 patients surviving more than 10 years after autotransplantation. These data provide insight into the molecular mechanisms of plasma-cell dyscrasias... - Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1Maurizio Zangari
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 141:433-44. 2008..These results provide a basis for the prospective evaluation of the consolidation strategy in a randomized clinical trial design... - TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3John D Shaughnessy
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 147:347-51. 2009..FGFR3+ and FGFR3- molecular subgroups fared worse in the presence of del TP53 when applying TT2 but not TT3. Thus, the prognostic implications of del TP53 were protocol-, genome-defined risk- and molecular subgroup-dependent... - High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2Yiming Zhou
Donna D and Donald M Lambert Laboratory for Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Proc Natl Acad Sci U S A 107:7904-9. 2010..Silencing of AGO2 dramatically decreased viability in MM cell lines. Genome-wide elevated expression of miRNAs in high-risk MM may be secondary to deregulation of AGO2 and the enzyme complexes that regulate miRNA maturation and function... - The Arkansas approach to therapy of patients with multiple myelomaBart Barlogie
Myeloma Institute for Research and Therapy, UAMS, Little Rock, AR, USA
Best Pract Res Clin Haematol 20:761-81. 2007.... - Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment armsBart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
J Clin Oncol 28:3023-7. 2010..After further follow-up of 87 months, we examined, in reiterative analyses, the effect of increasing time intervals on clinical outcomes relevant to baseline prognostic variables and treatment randomization... - Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular geneticsJohn D Shaughnessy
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 137:530-6. 2007.... - Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myelomaBart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
Clin Lymphoma Myeloma 6:469-74. 2006..Complete response has been considered a surrogate for favorable long-term outcome in multiple myeloma. Data on the impact of the duration of response on prognosis are lacking... - Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989Bart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham, Little Rock, AR 72205, USA
Blood 111:94-100. 2008..While the risk of MDS-CAs was low and clinical MDS occurred infrequently, monitoring after post-HDT consolidation chemotherapy appears warranted... - Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designsBart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
Cancer 112:2720-5. 2008..Total Therapy (TT) programs are complex and their execution over the course of several years is fraught with patient attrition due to failure and toxicity of therapy and patient/physician acceptance... - Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3John D Shaughnessy
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock AR, USA
Blood 118:3512-24. 2011..We are investigating whether second-generation proteasome inhibitors (eg, carfilzomib) can overcome resistance associated with high PSMD4 levels... - Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implicationsRonald Walker
Department of Radiology, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
J Clin Oncol 25:1121-8. 2007..Magnetic resonance imaging (MRI) permits the detection of diffuse and focal bone marrow infiltration in the absence of osteopenia or focal osteolysis on standard metastatic bone surveys (MBSs)... - The molecular classification of multiple myelomaFenghuang Zhan
Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 108:2020-8. 2006..A subset of cases with a predominating myeloid gene expression signature, excluded from the profiling analyses, had more favorable baseline characteristics and superior prognosis to those lacking this signature... - A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1John D Shaughnessy
Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 109:2276-84. 2007..Our data suggest that altered transcriptional regulation of genes mapping to chromosome 1 may contribute to disease progression, and that expression profiling can be used to identify high-risk disease and guide therapeutic interventions... - Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantationJumei Shi
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 143:641-53. 2008..Encouragingly, 50% of patients achieved (near) complete remission. These data set the stage for future studies of KIR-ligand mismatched NK cell therapy in the autologous setting... - F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myelomaTwyla B Bartel
Department of Radiology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 114:2068-76. 2009..Our results provide a rationale for testing the hypothesis that myeloma survival can be improved by altering treatment in patients in whom FDG suppression cannot be achieved after induction therapy... - Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulationMaurizio Zangari
The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72205, USA
Br J Haematol 126:715-21. 2004..The rate of DVT recurrence observed in our study upon thalidomide resumption was sufficiently low to allow its continuation in patients who may benefit from this therapeutic intervention... - Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survivalMaurizio Zangari
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
Clin Lymphoma 4:32-5. 2003..002), and creatinine level > or = 2 mg/dL (P < 0.001). However, the development of DVT did not adversely affect survival when examined as a time-dependent variable and adjusted for standard risk features (hazard ratio, 0.8; P = 0.162)... - Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myelomaSusann Szmania
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
J Immunother 30:847-54. 2007..MAGE-A3 immunization may be a useful adjunct to high dose melphalan-based peripheral blood stem cell transplant, providing a new therapeutic option for high-risk MM... - Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenanceSaad Z Usmani
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 120:1597-600. 2012..38; P = .09). These trials are registered at www.clinicaltrials.gov as NCT00573391 (TT2), NCT00081939 (TT3A), and NCT00572169 (TT3B)... - Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myelomaJumei Shi
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 111:1309-17. 2008..Our findings have clear therapeutic implications for MM and other NK cell-sensitive malignancies in the context of both allogeneic and autologous adoptively transferred NK cells... - Long-term outcome results of the first tandem autotransplant trial for multiple myelomaBart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Br J Haematol 135:158-64. 2006..038). Ten-year EFS and OS could be accomplished in 15% and 33% of patients, respectively, when all agents available in 1989, especially high-dose melphalan, were applied together upfront for the management of myeloma... - Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103Amberly Moreno-Bost
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
Cytotherapy 13:618-28. 2011.... - First thalidomide clinical trial in multiple myeloma: a decadeFrits van Rhee
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 112:1035-8. 2008..The poor outcome associated with lambda-type myeloma may relate to its overrepresentation in molecularly defined high-risk disease gleaned from studies in newly diagnosed myeloma... - Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantatioIchiro Hanamura
Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W. Markham St. #776, Little Rock, AR 72205, USA
Blood 108:1724-32. 2006..027). The proportion of cells with Amp1q21 and the copy number of 1q21 tended to increase at relapse compared with diagnosis. Our data suggest that Amp1q21 is associated with both disease progression and poor prognosis... - Con: allogeneic transplantation in multiple myelomaFrits van Rhee
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Clin Adv Hematol Oncol 4:391-4. 2006 - Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1Christoph J Heuck
University of Arkansas for Medical Sciences, Little Rock, AR, USA
Clin Cancer Res 18:5499-506. 2012.... - Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myelomaRamesh B Batchu
Myeloma Institute for Research and Therapy, Section for Gene and Immunotherapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
Cancer Res 65:10041-9. 2005..Thus, PTD-NY-ESO-1 accesses the cytoplasm by protein transduction, is processed by the proteasome, and NY-ESO-1 peptides presented by HLA class I elicit NY-ESO-1-specific T lymphocytes... - Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling dataSarah Waheed
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Haematologica 98:71-8. 2013..Clinicaltrials.gov identifier: NCT00081939)... - Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciencesBart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham, 816, Little Rock, AR 72205
J Clin Oncol 28:1209-14. 2010.... - Treatment advances in multiple myelomaGuido Tricot
The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 125:24-30. 2004 - NY-ESO-1 immunotherapy for multiple myelomaSusann Szmania
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Leuk Lymphoma 47:2037-48. 2006..NY-ESO-1 based therapies are already being tested in clinical trials for a multitude of tumors. This review discusses the potential of NY-ESO-1 immunotherapy to improve outcome for myeloma... - Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cellsFenghuang Zhan
Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
Blood 99:1745-57. 2002..Thus, novel candidate MM disease genes have been identified using gene expression profiling and this profiling has led to the development of a gene-based classification system for MM... - Interleukin-6 Receptor Polymorphism Is Prevalent in HIV-negative Castleman Disease and Is Associated with Increased Soluble Interleukin-6 Receptor LevelsKatie Stone
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America
PLoS ONE 8:e54610. 2013..These data suggest that interleukin-6 receptor polymorphism may be a contributing factor in Castleman Disease, and further research is warranted... - Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agentsSaad Z Usmani
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
Haematologica 97:1761-7. 2012..We evaluated the impact of this disease feature on patients' outcome in the context of novel agents... - Predicting long-term survival in multiple myeloma patients following autotransplantsAthanasios B T Fassas
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham St, Little Rock, AK 72205, USA
Leuk Lymphoma 44:749-58. 2003..Furthermore, patients with less favorable outcome should be identified early in their disease course and should be managed with novel and hopefully more effective treatments... - Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioningAshraf Badros
Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
J Clin Oncol 20:1295-303. 2002..We present our experience with relapsed and recently diagnosed patients with high-risk multiple myeloma (MM) receiving immunosuppressive, nonmyeloablative melphalan (MEL)-based conditioning regimens (mini-allograft)... - Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in boneXin Li
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
Stem Cells 29:263-73. 2011..This study suggests that altering the bone marrow microenvironment with PDAC cytotherapy attenuates growth of myeloma and that PDAC cytotherapy is a promising therapeutic approach for myeloma osteolysis... - Allografting or autografting for myelomaFrits van Rhee
N Engl J Med 356:2646-8; author reply 2646-8. 2007 - High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosisFrits van Rhee
Blood 110:827-32. 2007..65, P = .003). Unlike baseline and follow-up analyses of serum and urine M-proteins, high SFLC levels at baseline-reflecting more aggressive disease-and steeper reductions after therapy identified patients with inferior survival... - Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profilingJeffrey Haessler
Cancer Research and Biostatistics, Seattle, Washington, USA
Clin Cancer Res 13:7073-9. 2007..To determine whether the clinical benefit of complete remission (CR) may depend on prognostic subgroups of patients with multiple myeloma... - Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapyGuido Tricot
University of Utah School of Medicine, 30N 1900E, 5C402, Salt Lake City, UT 84132 USA
Haematologica 93:1739-42. 2008..001) and (v) platelet recovery was faster after first transplant (when less stem cells were infused) (p=0.01). Pegfilgrastim may be considered the standard of care for stem cell mobilization... - CS1, a potential new therapeutic antibody target for the treatment of multiple myelomaEric D Hsi
Clinical Pathology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
Clin Cancer Res 14:2775-84. 2008....
Research Grants
- Potentiating Natural Killer Cell Anti-Myeloma EffectsFrits van Rhee; Fiscal Year: 2009..This grant proposal describes 3 new ways in which the patient's own immune cells can be used to destroy the cancer. Such treatment may also be useful to treat other cancers. ..
- Potentiating Natural Killer Cell Anti-Myeloma EffectsFrits van Rhee; Fiscal Year: 2010..This grant proposal describes 3 new ways in which the patient's own immune cells can be used to destroy the cancer. Such treatment may also be useful to treat other cancers. ..
- Potentiating Natural Killer Cell Anti-Myeloma EffectsFrits van Rhee; Fiscal Year: 2009..This grant proposal describes 3 new ways in which the patient's own immune cells can be used to destroy the cancer. Such treatment may also be useful to treat other cancers. ..